Novartis Ag

Novartis Pharma Gmbh

Juerg Zimmermann

Werner Breitenstein

Hans Michael Buerger

Paul William Manley

Giorgio Caravatti

Keiichi Masuya

Philipp Grosche

Nils Ostermann

Edgar Jacoby

Fumiaki Yokokawa

Juergen Klaus Maibaum

Andreas Marzinzik

Takanori Kanazawa

Kazuhide Konishi

Shimpei Kawakami

Peter End

Margaret A Cudd

Claus Erhardt

Ulrike Pfaar

Bertrand Sutter

Gerhard Gross

K Olaf Börnsen

The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-yl-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I, which may be used for example for tumour therapy.

Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification. 

Organic compounds

The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula (I) wherein the substituents are defined as in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

N-phenyl-2-pyrimidine-amine derivatives

Growing community of inventors

Reinach, Switzerland

Juerg Zimmermann